Inozyme Pharma, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Inozyme Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Inozyme Pharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$24.9M, a 37.5% decline year-over-year.
  • Inozyme Pharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$99.7M, a 37.7% decline year-over-year.
  • Inozyme Pharma, Inc. annual Operating Income (Loss) for 2023 was -$75.6M, a 10.1% decline from 2022.
  • Inozyme Pharma, Inc. annual Operating Income (Loss) for 2022 was -$68.7M, a 21.2% decline from 2021.
  • Inozyme Pharma, Inc. annual Operating Income (Loss) for 2021 was -$56.6M, a 0.69% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$75.6M -$6.97M -10.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-12
2022 -$68.7M -$12M -21.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-12
2021 -$56.6M +$395K +0.69% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-22
2020 -$57M -$36.2M -174% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-15
2019 -$20.8M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.